HS
CRSP icon

Horan Securities’s CRISPR Therapeutics CRSP Stock Holding History

Horan Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10
Closed -$561 – 208
2023
Q2 		$561 Hold
10
– – ﹤0.01% 656
2023
Q1 		$452 Hold
10
– – ﹤0.01% 680
2022
Q4 		$407 Hold
10
– – ﹤0.01% 726
2022
Q3 		$1K Hold
10
– – ﹤0.01% 532
2022
Q2 		$1K Hold
10
– – ﹤0.01% 605
2022
Q1 		$1K Hold
10
– – ﹤0.01% 476
2021
Q4 		$1K Buy
+10
New +$874 ﹤0.01% 475
2021
Q2 		$2K Hold
10
– – ﹤0.01% 403
2021
Q1 		$1K Buy
+10
New +$1.51K ﹤0.01% 386

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Horan Securities's CRSP Position: Q3 2023 in Review

Horan Securities sold out of CRISPR Therapeutics (CRSP) in Q3 2023, closing a stake of 10 shares — an estimated $561 sold.

Horan Securities first reported a position in CRSP in Q1 2021 and held it in 9 quarters. The position peaked at $2K in Q2 2021. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

  • Horan Securities reported no remaining CRISPR Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Horan Securities sold 10 CRISPR Therapeutics shares in Q3 2023, an estimated $561.
  • Horan Securities first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 9 quarters.
  • Horan Securities's CRISPR Therapeutics position peaked at $2K in Q2 2021.
  • 406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on Horan Securities's 13F filing for Q3 2023, filed 1 Nov 2023.